Cancer trial readouts to watch at ESMO; Merck chemo drug deal worth up to $22 billion

At the European Society for Medical Oncology, new data from trials in lung, prostate, and other types of cancer

October 20, 2023 Check out STAT+

Sponsored By

Adobe STAT+ | What to watch at ESMO: readouts from trials in lung, prostate, and other types of cancer Here are the presentations we'll be keeping an eye on at this year's conference of the European Society for Medical Oncology. By Andrew Joseph STAT+ | Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion The two companies will partner on three targeted chemotherapy treatments, known as antibody-drug conjugates. By Andrew Joseph Breast cancer is deadlier for Black women. A study of mammograms could help close the gap Are 3D mammograms better than standard 2D imaging for catching advanced breast cancer? A clinical trial is trying to find out. By Associated Press

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser